Ovid Therapeutics Inc. — Revenue by Fiscal Year
6 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/92199aff-b47a-4aa8-97a8-ba91350c58fc/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $7.3M | 2025-01-01 – 2025-12-31 | evidence 0001628280-26-019438 |
| FY 2024 | $223.6M | 2014-04-01 – 2025-03-31 | evidence 0001628280-25-024913 |
| FY 2023 | $223.0M | 2014-04-01 – 2024-03-31 | evidence 0001628280-24-023067 |
| FY 2022 | $222.6M | 2014-04-01 – 2023-03-31 | evidence 0001628280-23-016013 |
| FY 2021 | $222.4M | 2014-04-01 – 2022-03-31 | evidence 0000950170-22-008739 |
| FY 2020 | $221.0M | 2014-04-01 – 2021-03-31 | evidence 0001564590-21-027623 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Ovid Therapeutics Inc. — all facts · Net Income · Operating Income